The firm said the funds will enable completion of clinical validation of its first blood-based cancer screening product ahead of an anticipated 2025 launch.

The order-dependent contract is for maintenance and support of a version of the BioFire FilmArray 2.0 molecular diagnostic instrument through January 2029.

A US district court awarded the judgment against a Kentucky lab owner accused of billing Medicare for molecular testing not ordered by a healthcare provider.

The company, formerly known as Progenity, was accused of violating consumer protection laws by making misleading claims about the costs of its genetic testing services.

The BRAHMS CgA II KRYPTOR immunoassay is for use to track tumor progression for neuroendocrine cancer patients by measuring CgA concentration in serum.

The New York-based firm will use the funds to scale access to its testing, discover new vaginal health biomarkers, and validate outcomes of its service.

Investigators will work with the company to study the correlation between test results and patient outcomes after localized treatment in a UK cohort.

The company said that its secured creditors have recapitalized its operating subsidiaries and restructured its balance sheet to reduce its debt burden by €132 million. 

The SEC informed CareDx in a letter that it had concluded an investigation into the company's accounting and public reporting practices.

The quality controls are designed to verify the performance of the Luminex Verigene Blood Culture Gram-Positive and Gram-Negative tests.